

The management of CML: current treatment paradigms and future perspectives

An educational day for European fellows on behalf of EUTOS for CML

Policlinico Universitario, Naples

18 – 19 May 2009

Session 1: First-line treatment approaches in CML – Monday 18 May Chaired by F Pane and M Baccarani

14.00	Introduction and objectives	F Pane
14.10	The biology of CML	G Saglio
14.35	First line treatment of CML with imatinib: the IRIS trial and the GIMEMA trials	M Baccarani
15.05	Unsatisfactory treatment response: more imatinib or 2 nd generation TK inhibitors?	G Rosti

15.35 REFRESHMENT BREAK

15.55	Living with CML: practical management and long-term treatment effects	L Luciano
16.15	CML in elderly patients and children	G Rosti
16.35	Q & A session	Panel
16.50	<i>Clinical case presentations 1 & 2:</i> Optimal response to imatinib treatment and management of the patient Late response to treatment	A Hochhaus S Saussele
17.10	Session wrap-up	M Baccarani

17.15 SESSION CLOSE

Session 2: Prognostic factors for treatment response in CML – Tuesday 19 May Chaired by G Martinelli and A Hochhaus

08.30	Welcome back	G Martinelli
08.35	BCR-ABL quantitation and mutation detection: methods of disease monitoring and the challenge of standardization	A Hochhaus
09.00	The role of stem cell transplantation in CML treatment, and accelerated and blast phase management	S Saussele
09.15	Metabolism of imatinib and other TK inhibitors: importance of blood level testing	FX Mahon
09.40	Cellular and molecular mechanisms of imatinib resistance	A Hochhaus
10.00	Q & A session	Panel
10.15	<i>Clinical case presentations 3 & 4:</i> Suboptimal response to imatinib with dose increase rescue Failure of treatment in a young high Sokal risk patient	G Martinelli G Rosti



10.35

REFRESHMENT BREAK

Session 3: Second-line treatment approaches in CML – Tuesday 19 May

Chaired by R Hehlmann and G Saglio

10.50	New generation TK inhibitors in patients with treatment resistance	G Martinelli
11.10	New generation TK inhibitors in front-line therapy	F Pane
11.30	Minimal residual disease in responding patients: therapeutic strategies	G Saglio
11.50	Updated ELN recommendations for the management of CML	F Pane
12.10	Q & A session	Panel
12.25	<i>Clinical cases 5 & 6:</i> Failure of treatment due to mutation	F Pane
	Young woman with good response to imatinib wishing to get pregnant	A Hochhaus
12.45	Closing address: EUTOS for CML - an innovative collaboration between ELN and Novartis	R Hehlmann

13.00

CLOSE